Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Can-Fite BioPharma is a privately-held biopharmaceutical company that began operations in 2000. The company was
founded on the basis of the scientific work of Professor Pnina Fishman, a tumour immunologist from the Rabin Medical
Center in Israel. In addition to its Israeli headquarters, the company also has a US-based senior management team in
Boxborough, MA, that is involved in the company's preclinical and clinical development. Its Israeli research and
development facilities include a molecular biology, cell biology and a modern animal facility.